News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Drug interactions and pharmacokinetics
Once daily Kaletra: dose escalation rarely the answer for those with low plasma levels

Even after dose escalation, plasma concentrations of once-daily Kaletra (lopinavir/ritonavir) rarely reach therapeutic levels in some patients, according to a study published in the July

Published
21 June 2005
By
Michael Carter
Side-effects
Duration of ddI treatment and dose risk factors for CD4 loss in patients taking ddI/tenofovir

Duration of ddI (Videx) therapy and ddI dose are risk factors for the loss of CD4 T-cells in patients with a controlled viral load taking

Published
21 June 2005
By
Michael Carter
Drug interactions and pharmacokinetics
Tenofovir may linger up to 3 weeks in body: discontinue with caution

Sub-optimal levels of tenofovir (Viread) that could lead to drug resistance may linger in the body for at least three weeks after the drug is

Published
14 June 2005
By
Keith Alcorn
Contraception
Increased risk of oral contraceptive failure with nelfinavir

HIV-positive women taking oral contraceptives and the protease inhibitor nelfinavir are significantly more likely to experience contraceptive failure and become pregnant, according to a retrospective

Published
07 September 2004
By
Michael Carter
Drug interactions and pharmacokinetics
What to do with nelfinavir?

Two studies presented on Monday at the 40th ICAAC raised some difficult questions about the role of nelfinavir in antiretroviral therapy. Nelfinavir is one of

Published
05 March 2001
By
Keith Alcorn
← Prev1...1011121314Next →

Filter by country